CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2011	Mar. 31, 2010
Cash flows from operating activities:
Net income (loss):	$ (1,612,625)	$ 1,987,178	$ (43,509)	$ (4,063,844)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	1,274,597	1,274,247	1,674,528	1,378,999
Stock-based compensation expense	730,136	748,235	1,003,266	1,006,798
Deferred tax expense	15,744
Gain on bargain purchase	(427,478)
Loss on revaluation of contingent consideration	28,182
Loss on disposal of assets	2,826		5,597	905
Changes in assets and liabilities:
Accounts receivable	3,551,969	(601,141)	(689,569)	(29,259)
Royalties receivable	(694,238)	(450,600)	(216,602)	(259,200)
Inventories	(870,252)	263,570	247,164	212,087
Prepaid expenses and other current assets	(190,007)	(708,311)	986,340	(545,522)
Accounts payable	247,222	(291,824)	(60,404)	(931,567)
Accrued liabilities	243,182	(408,224)	383,237	782,200
Long-term liabilities	11,487	(25,447)	(58,285)	49
Net cash provided by (used in) operating activities	2,310,745	1,787,683	3,231,763	(2,448,354)
Cash flows from investing activities:
Purchases of marketable securities	(49,465,924)	(58,095,140)	(84,329,731)	(47,038,060)
Sales of marketable securities	26,290,378
Redemptions of marketable securities	45,624,819	54,225,000	83,650,417	59,336,807
Purchases of property, plant and equipment	(575,455)	(317,982)	(524,666)	(597,349)
Net cash (used in) provided by investing activities	(5,010,610)	(4,488,122)	(1,503,980)	9,921,398
Cash flows from financing activities:
Exercise of stock options	25	25,758	6,571	53,991
Repurchase and retirement of treasury stock	(330,867)
Principal payments under capital lease obligations		(56,850)	(56,850)	(42,405)
Net cash (used in) provided by financing activities	(330,842)	(31,092)	(50,279)	11,586
Effect of exchange rate changes on cash and cash equivalents	(5,092)
Net (decrease) increase in cash and cash equivalents	(3,035,799)	(2,731,531)	1,677,504	7,484,630
Cash and cash equivalents, beginning of period	14,203,544	12,526,040	12,526,040	5,041,410
Cash and cash equivalents, end of period	11,167,745	9,794,509	14,203,544	12,526,040
Supplemental disclosure of cash flow information:
Income taxes refunded				(135,157)
BioFlash Partners, LLC
Cash flows from investing activities:
Payment for acquisition of business		(300,000)	(300,000)	(1,780,000)
Supplemental disclosure of non-cash investing activities:
Contingent consideration transferred in acquisition				560,000
Novozymes
Cash flows from investing activities:
Payment for acquisition of business	(26,884,428)
Supplemental disclosure of non-cash investing activities:
Contingent consideration transferred in acquisition	$ 1,610,560